---
title: "ZIF-90-PQ Cascade Nanoplatform (CP@ZIF-PQ/Ce6) for Multimodal Breast Cancer Therapy"
id: "pubmed-42532321"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42532321"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42532321/"
doi: "10.1016/j.ijpharm.2026.127255"
published_at: "2026-09-05T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# ZIF-90-PQ Cascade Nanoplatform (CP@ZIF-PQ/Ce6) for Multimodal Breast Cancer Therapy
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42532321
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42532321/)
- **DOI:** [10.1016/j.ijpharm.2026.127255](https://doi.org/10.1016%2Fj.ijpharm.2026.127255)
- **Published At:** 2026-09-05T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The study reports a **ZIF-90-based multimodal nanosystem** named CP@ZIF-PQ/Ce6 NPs designed for breast cancer treatment, combining multiple therapeutic modalities to overcome tumor microenvironment limitations. - The nanosystem is loaded with **copper peroxide (CP)** nanoparticles, the autophagy inhibitor **primaquine phosphate (PQ)**, and the photosensitizer **Ce6** to integrate photodynamic therapy (PDT), chemodynamic therapy (CDT), oxygen generation, and autophagy inhibition. - The combined PDT/CDT/O2-generation/autophagy-inhibition strategy is intended to increase **reactive oxygen species (ROS)** production, relieve tumor hypoxia, and prevent autophagy-mediated tumor cell protection. - CP@ZIF-PQ/Ce6 NPs exhibit **dual pH- and ATP-responsive** behavior, enabling triggered drug release within the tumor microenvironment. - The authors report potent antitumor activity and favorable biocompatibility of the nanosystem in both in vitro and in vivo models, demonstrating feasibility of multimodal cooperative therapy. - The work positions multimodal, tumor-microenvironment–responsive nanosystems as a promising strategy to address the intrinsic limitations of monotherapy in solid tumors such as breast cancer. - Keywords emphasized in the study include **antitumor**, **autophagy inhibition therapy**, **chemodynamic and photodynamic therapy**, **multimodal therapy**, and **ZIF-90**.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42532321/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42532321%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42532321/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42532321/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42532321/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42532321/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42532321/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42532321%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42532321%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42532321/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42532321/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42532321/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42532321/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Elsevier Science full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif) Elsevier Science ](https://linkinghub.elsevier.com/retrieve/pii/S0378-5173\(26\)00703-9 "See full text options at Elsevier Science") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42532321/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42532321/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42532321/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42532321/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42532321/#conflict-of-interest) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42532321/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42532321/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42532321/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42532321/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42532321/#linkout) Title & authors Abstract Conflict of interest statement Similar articles MeSH terms Substances Related information LinkOut - more resources Int J Pharm Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Int+J+Pharm%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Int+J+Pharm%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) . 2026 Sep 5:702:127255. doi: 10.1016/j.ijpharm.2026.127255. Epub 2026 Jul 30. # ZIF-90-PQ-based cascade nanoplatform for multimodal cooperative treatment of breast cancer [Pingfei Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+P&cauthor_id=42532321)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42532321/#full-view-affiliation-1 "Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China."), [Yongqi Liu](https://pubmed.ncbi.nlm.nih.gov/?term=Liu+Y&cauthor_id=42532321)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42532321/#full-view-affiliation-1 "Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China."), [Jie Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+J&cauthor_id=42532321)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42532321/#full-view-affiliation-1 "Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China."), [Tianyi Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+T&cauthor_id=42532321)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42532321/#full-view-affiliation-1 "Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China."), [Shiming Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+S&cauthor_id=42532321)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42532321/#full-view-affiliation-2 "Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China. Electronic address: 2111110690@bjmd.edu.cn."), [Xinggang Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+X&cauthor_id=42532321)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42532321/#full-view-affiliation-3 "Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China. Electronic address: yangxg321@163.com.") Affiliations Expand ### Affiliations * 1 Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China. * 2 Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China. Electronic address: 2111110690@bjmd.edu.cn. * 3 Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China. Electronic address: yangxg321@163.com. * PMID: **42532321** * DOI: [ 10.1016/j.ijpharm.2026.127255 ](https://doi.org/10.1016/j.ijpharm.2026.127255) Item in Clipboard # ZIF-90-PQ-based cascade nanoplatform for multimodal cooperative treatment of breast cancer Pingfei Li et al. Int J Pharm. 2026. Show details Display options Display options Format Abstract PubMed PMID Int J Pharm Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Int+J+Pharm%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Int+J+Pharm%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) . 2026 Sep 5:702:127255. doi: 10.1016/j.ijpharm.2026.127255. Epub 2026 Jul 30. ### Authors [Pingfei Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+P&cauthor_id=42532321)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42532321/#short-view-affiliation-1 "Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China."), [Yongqi Liu](https://pubmed.ncbi.nlm.nih.gov/?term=Liu+Y&cauthor_id=42532321)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42532321/#short-view-affiliation-1 "Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China."), [Jie Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+J&cauthor_id=42532321)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42532321/#short-view-affiliation-1 "Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China."), [Tianyi Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+T&cauthor_id=42532321)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42532321/#short-view-affiliation-1 "Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China."), [Shiming Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+S&cauthor_id=42532321)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42532321/#short-view-affiliation-2 "Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China. Electronic address: 2111110690@bjmd.edu.cn."), [Xinggang Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+X&cauthor_id=42532321)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42532321/#short-view-affiliation-3 "Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China. Electronic address: yangxg321@163.com.") ### Affiliations * 1 Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China. * 2 Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China. Electronic address: 2111110690@bjmd.edu.cn. * 3 Shenyang Pharmaceutical University, School of Pharmacy, No.103 Wenhua Road, Shenyang 110016, China. Electronic address: yangxg321@163.com. * PMID: **42532321** * DOI: [ 10.1016/j.ijpharm.2026.127255 ](https://doi.org/10.1016/j.ijpharm.2026.127255) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract Owing to the complexity of the tumor microenvironment, monotherapy often suffers from inherent limitations and fails to achieve satisfactory antitumor efficacy. Therefore, multimodal collaborative therapy has become a trend. In this study, CP@ZIF-PQ/Ce6 NPs, a ZIF-90-based multimodal nanosystem loaded with copper peroxide (CP) nanoparticles, the autophagy inhibitor primaquine phosphate (PQ) and the photosensitizer Ce6, were developed. This nanosystem enables the integration of photodynamic therapy (PDT), chemodynamic therapy (CDT), oxygen generation, and autophagy inhibition. Through the combined therapeutic effects of PDT/CDT/O2 generation/autophagy inhibition, CP@ZIF-PQ/Ce6 NPs enhance the production of reactive oxygen species(ROS), alleviate tumor hypoxia, and block the autophagy-mediated protective pathway in tumor cells. Moreover, the nanosystem exhibits dual pH- and ATP-responsive properties, allowing tumor microenvironment-triggered drug release. CP@ZIF-PQ/Ce6 NPs successfully integrate PDT, CDT, oxygen-generating therapy, and autophagy inhibition, demonstrating potent antitumor activity and favorable biocompatibility both in vitro and in vivo. This study provides an innovative strategy and experimental evidence for multimodal collaborative antitumor therapy to overcome the limitations of monotherapy imposed by the tumor microenvironment. **Keywords:** Antitumor; Autophagy inhibition therapy; Chemodynamic and photodynamic therapy; Multimodal therapy; ZIF-90. Copyright © 2026 Elsevier B.V. All rights reserved. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ## Similar articles * [ Self-Amplified pH/ROS Dual-Responsive Co-Delivery Nano-System with Chemo-Photodynamic Combination Therapy in Hepatic Carcinoma Treatment. ](https://pubmed.ncbi.nlm.nih.gov/38699684/) Huang Y, Wu S, Li J, He C, Cheng Y, Li N, Wang Y, Wu Y, Zhang J.Huang Y, et al.Int J Nanomedicine. 2024 Apr 24;19:3737-3751. doi: 10.2147/IJN.S453199. eCollection 2024.Int J Nanomedicine. 2024.PMID: 38699684Free PMC article. * [ Ce6-DNAzyme-Loaded Metal-Organic Framework Theranostic Agents for Boosting miRNA Imaging-Guided Photodynamic Therapy in Breast Cancer. ](https://pubmed.ncbi.nlm.nih.gov/40761027/) Yang Z, Qin R, Ruan D, Hu C, Li W, Zhou J, Zhang F, Guo B, Huang L, Jaque D, Shen Y, Wang F.Yang Z, et al.ACS Nano. 2025 Aug 5;19(30):27873-27889. doi: 10.1021/acsnano.5c09287. Epub 2025 Jul 26.ACS Nano. 2025.PMID: 40761027 * [ Aggregation-Induced Emission Photosensitizer-Engineered Anticancer Nanomedicine for Synergistic Chemo/Chemodynamic/Photodynamic Therapy. ](https://pubmed.ncbi.nlm.nih.gov/38115727/) Yu B, Liu M, Jiang L, Xu C, Hu H, Huang T, Xu D, Wang N, Li Q, Tang BZ, Huang X, Zhang W.Yu B, et al.Adv Healthc Mater. 2024 Apr;13(11):e2303643. doi: 10.1002/adhm.202303643. Epub 2023 Dec 25.Adv Healthc Mater. 2024.PMID: 38115727 * [ Cu-Cy Nps@ZIF-8@HA-Mediated Photodynamic Therapy for Cutaneous Squamous Cell Carcinoma. ](https://pubmed.ncbi.nlm.nih.gov/41836720/) Li N, Wan X, Hou X, Zhang J, Zhang C, Sun Y, Wang F, Kong S, Yang C, Jiang G.Li N, et al.Int J Nanomedicine. 2026 Jan 8;21:560049. doi: 10.2147/IJN.S560049. eCollection 2026.Int J Nanomedicine. 2026.PMID: 41836720Free PMC article. * [ Nanosystem-Mediated Phototherapy (PDT/PTT) - Chemodynamic Therapy for Synergistic Antitumor Therapy: Strategies and Advances. ](https://pubmed.ncbi.nlm.nih.gov/42569610/) Ma Y, Gong J, Wu Z, Tang X, Xia X, Yan H.Ma Y, et al.Int J Nanomedicine. 2026 Aug 3;21:628088. doi: 10.2147/IJN.S628088. eCollection 2026.Int J Nanomedicine. 2026.PMID: 42569610Free PMC article.Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42532321) ## MeSH terms * Animals Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Animals%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Animals) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * Antineoplastic Agents* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * Autophagy / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Autophagy%2Fdrug+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Autophagy) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * Breast Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * Breast Neoplasms* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * Cell Line, Tumor Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Line%2C+Tumor%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Line%2C+Tumor) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * Combined Modality Therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Combined+Modality+Therapy%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Combined+Modality+Therapy) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * Female Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Female) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * Metal-Organic Frameworks Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Metal-Organic+Frameworks%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Metal-Organic+Frameworks) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * Mice Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mice%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Mice) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * Mice, Inbred BALB C Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mice%2C+Inbred+BALB+C%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Mice%2C+Inbred+BALB+C) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * Mice, Nude Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mice%2C+Nude%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Mice%2C+Nude) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42532321/) * Nanoparticles* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Nanoparticles%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Se
## Related Clinical Research

- [Fluorinated Nanohybrid Micelles with Lutetium-177 and Gold for Potentiated Internal Radiotherapy](https://medichelpline.com/clinical-feed/pubmed-42476272.md) (DOI: 10.1016/j.ijpharm.2026.127219)
- [Directional coating of cell membranes preserves orientation and extends circulation of biomimetic](https://medichelpline.com/clinical-feed/pubmed-42508509.md) (DOI: 10.1016/j.ijpharm.2026.127241)
- [FDA Grants Accelerated Approval to Etcamah for ESR1-Mutant HR+/HER2− Advanced Breast Cancer](https://medichelpline.com/clinical-feed/fda-news-releases-1-fda-grants-accelerated-approval-to-a-new-breast-cancer-treatment.md)
- [Vitamin D limits mammary cancer bone invasion by reducing inflammation and EMT](https://medichelpline.com/clinical-feed/biorxiv-0-vitamin-d-counters-bone-invasion-by-mammary-cancer-through-inhibition-of.md)
- [PDAC cells cross endothelium by filopodia-driven invasion or endothelial retraction](https://medichelpline.com/clinical-feed/biorxiv-9-pancreatic-cancer-cells-breach-endothelial-barriers-through-protrusion-driven.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.